Trade details
Astera Labs, Inc. (NASDAQ: ALAB) disclosed that its Chief Executive Officer sold a total of 123,750 shares of common stock on April 10, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The combined proceeds from the two transactions amounted to $18,522,445.
The disposition was split into two blocks. The first block comprised 99,023 shares sold at a weighted average price of $149.5322, producing $14,800,267 in proceeds. Prices within that block ranged from $149.0000 to $149.9900. The second block consisted of 24,727 shares sold at a weighted average price of $150.2535, generating $3,715,178, with trade prices for that lot ranging from $150.0000 to $150.6300.
Holding structure and plan mechanics
The shares sold were indirectly held by a Living Trust. Following completion of the April 10 trades, the CEO continues to indirectly hold 4,407,982 shares through the same Living Trust.
The filing states the sales were executed automatically under a Rule 10b5-1 trading plan that the CEO adopted on December 1, 2025. The filing does not attach further commentary beyond the mechanical details of the trades and the residual indirect holdings.
Market context and valuation note
Astera Labs shares have gained 187% over the past year and the stock was trading at $170.58 at the time of the disclosure. The company's market capitalization is reported at $29.07 billion. An InvestingPro analysis referenced in the filing indicates the stock appears overvalued at current levels; the filing does not provide additional valuation metrics beyond that characterization.
Recent financial performance
Separately, Astera Labs reported fourth-quarter 2025 results that outperformed expectations. The company posted earnings per share of $0.58, exceeding the anticipated $0.51, a beat of 13.73%. Revenue for the quarter was $270.6 million, a year-over-year increase of 92%.
The filing notes there were no reported merger developments tied to the company and indicates there are no current updates regarding analyst upgrades or downgrades. Those items were listed alongside the other recent disclosures about the company.
Takeaway
The Form 4 filing records an automatic sale under a prearranged plan and clarifies that the sold shares were held indirectly by a Living Trust. The disclosure accompanies robust quarterly results and a sharp run-up in the share price over the prior year. The filing provides transaction-level detail without additional commentary about intent or future plans.
Summary of facts
- CEO sold 123,750 shares on April 10, 2026, totaling $18,522,445.
- Transactions executed in two blocks: 99,023 shares at $149.5322 weighted average; 24,727 shares at $150.2535 weighted average.
- Sales were automatic under a Rule 10b5-1 plan adopted December 1, 2025; shares were indirectly held by a Living Trust.
- Post-sale indirect holdings through the Living Trust stand at 4,407,982 shares.
- Astera Labs reported Q4 2025 EPS of $0.58 versus $0.51 expected and revenue of $270.6 million, up 92% year over year.